Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQC80I
|
|||
| Drug Name |
TRPH-222
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | ||
| Company |
Triphase Accelerator
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03682796) Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Triphase Accelerator. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.